[go: up one dir, main page]

MX2019007555A - Uso de bacterias de acido láctico para tratar o prevenir la diabetes mellitus gestacional. - Google Patents

Uso de bacterias de acido láctico para tratar o prevenir la diabetes mellitus gestacional.

Info

Publication number
MX2019007555A
MX2019007555A MX2019007555A MX2019007555A MX2019007555A MX 2019007555 A MX2019007555 A MX 2019007555A MX 2019007555 A MX2019007555 A MX 2019007555A MX 2019007555 A MX2019007555 A MX 2019007555A MX 2019007555 A MX2019007555 A MX 2019007555A
Authority
MX
Mexico
Prior art keywords
treat
lactic acid
acid bacteria
diabetes mellitus
gestational diabetes
Prior art date
Application number
MX2019007555A
Other languages
English (en)
Inventor
Lee Wickens Kristin
Original Assignee
Univ Of Otago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Of Otago filed Critical Univ Of Otago
Publication of MX2019007555A publication Critical patent/MX2019007555A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Dairy Products (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención proporciona métodos para tratar o prevenir la diabetes gestacional mediante la administración de lactobacillus rhamnosus HNO01 o derivados de esta, además de los usos, las composiciones y los medicamentos .que comprenden lactobacillus rhamnosus HNO01 o derivados de esta para tratar o prevenir la diabetes mellitus gestacional.
MX2019007555A 2016-12-22 2017-06-02 Uso de bacterias de acido láctico para tratar o prevenir la diabetes mellitus gestacional. MX2019007555A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ72791416 2016-12-22
PCT/IB2017/053262 WO2018115985A1 (en) 2016-12-22 2017-06-02 Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus

Publications (1)

Publication Number Publication Date
MX2019007555A true MX2019007555A (es) 2020-01-30

Family

ID=62624701

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007555A MX2019007555A (es) 2016-12-22 2017-06-02 Uso de bacterias de acido láctico para tratar o prevenir la diabetes mellitus gestacional.

Country Status (14)

Country Link
US (2) US11395839B2 (es)
EP (1) EP3558330B1 (es)
JP (1) JP7092380B2 (es)
KR (1) KR102513639B1 (es)
CN (1) CN110290795A (es)
AU (1) AU2017380603B2 (es)
CA (1) CA3047920C (es)
DK (1) DK3558330T3 (es)
MX (1) MX2019007555A (es)
MY (1) MY197917A (es)
NZ (1) NZ754706A (es)
PH (1) PH12019501439B1 (es)
RU (1) RU2769312C2 (es)
WO (1) WO2018115985A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018115985A1 (en) * 2016-12-22 2018-06-28 Wickens Kristen Lee Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus
EP4014756A1 (en) * 2020-12-15 2022-06-22 DuPont Nutrition Biosciences ApS Bioprocessing of protein with probiotic bacteria to improve amino acid and peptide availability
EP4267155A4 (en) * 2020-12-22 2024-11-20 Fonterra Co-Operative Group Ltd USE OF LACTIC ACID BACTERIA TO INHIBIT METHANOGEN GROWTH OR TO REDUCE METHANE EMISSIONS
CN114990004B (zh) * 2022-04-19 2023-09-15 尚品健康科技(青岛)有限公司 一种分泌型免疫球蛋白a包裹态罗伊氏乳杆菌及防治妊娠糖尿病的应用
WO2024158981A1 (en) * 2023-01-26 2024-08-02 Wisconsin Alumni Research Foundation Compositions and methods for reducing the rate of type 1 diabetes
CN116694537B (zh) * 2023-07-28 2023-10-31 善恩康生物科技（苏州）有限公司 鼠李糖乳酪杆菌及其在制备治疗2型糖尿病产品中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0909170A4 (en) 1996-07-01 2000-02-09 Sepracor Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF URINE INCONTINENCE USING ENANTIOMER-ENRICHED (S) -TRIDIHEXETHYL
TR200000451T2 (tr) * 1997-08-21 2000-06-21 New Zealand Dairy Board Bağışıklık arttırıcı laktik asit bakterileri.
US20030191193A1 (en) 2002-04-03 2003-10-09 Jillian Cornish Lactoferrin
US20090270309A1 (en) 2005-10-14 2009-10-29 Jillian Cornish Use of lactoferrin fragments and hydrolysates
AR060029A1 (es) 2006-03-02 2008-05-21 Unistraw Patent Holdings Ltd Pajilla para beber adaptada para acondicionar progresivamente un ingrediente activo y metodo de fabricar dicha pajilla
AR063571A1 (es) 2006-11-06 2009-02-04 Unistraw Patent Holdings Ltd Aparato para el agregado de agentes o ingredientes solubles a un líquido portador, para su administración oral a través de un sorbete
EP2011506A1 (en) * 2007-07-05 2009-01-07 Nestec S.A. Supplementation of maternal diet
US20110189149A1 (en) * 2008-06-20 2011-08-04 Remy Burcelin New Uses of Lactic Acid Bacteria and Bifidobacteria
US9737575B2 (en) * 2008-11-28 2017-08-22 University Of Otago Use of lactic acid bacteria to treat or prevent eczema
BR112012017978A2 (pt) 2010-01-19 2016-05-03 Abbott Lab fórmulas nutricionais contendo simbióticos
CA2983685A1 (en) 2015-06-11 2016-12-15 Nestec S.A. Dietary supplement comprising a probiotic and ferric pyrophosphate
WO2018115985A1 (en) * 2016-12-22 2018-06-28 Wickens Kristen Lee Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus

Also Published As

Publication number Publication date
US20200093873A1 (en) 2020-03-26
RU2019122811A3 (es) 2021-01-25
KR102513639B1 (ko) 2023-03-23
BR112019012965A2 (pt) 2019-11-26
CA3047920A1 (en) 2018-06-28
CA3047920C (en) 2022-07-19
RU2019122811A (ru) 2021-01-25
JP7092380B2 (ja) 2022-06-28
US20220387527A1 (en) 2022-12-08
NZ754706A (en) 2022-09-30
AU2017380603B2 (en) 2022-02-03
PH12019501439B1 (en) 2024-02-23
US11395839B2 (en) 2022-07-26
RU2769312C2 (ru) 2022-03-30
CN110290795A (zh) 2019-09-27
US12377125B2 (en) 2025-08-05
EP3558330B1 (en) 2022-09-21
WO2018115985A1 (en) 2018-06-28
DK3558330T3 (da) 2022-11-07
EP3558330A1 (en) 2019-10-30
EP3558330A4 (en) 2020-07-08
PH12019501439A1 (en) 2020-02-24
KR20190107032A (ko) 2019-09-18
JP2020502247A (ja) 2020-01-23
AU2017380603A1 (en) 2019-07-11
MY197917A (en) 2023-07-25

Similar Documents

Publication Publication Date Title
MX2019007555A (es) Uso de bacterias de acido láctico para tratar o prevenir la diabetes mellitus gestacional.
MX2017015938A (es) Inhibidores de ezh2 para el tratar linfomas.
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
MX376008B (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
MX2017011269A (es) Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos.
BR112017007144A2 (pt) ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição.
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MX354123B (es) Composición antiséptica oral para tratamiento de mucositis oral.
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
BR112016017193A2 (pt) Derivados de insulina, seus usos, e composição farmacêutica
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase
BR112017005209A2 (pt) compostos moduladores de pirrolopiridina substituída por metila e trifluorometila de rorc2 e seu uso
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
CL2017001025A1 (es) Compuestos para usarse en el tratamiento antihelmíntico
MX2017015292A (es) Composicion para tratar lesiones cerebrales.
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?